Document is current
Any future updates will be listed below
-
Authors
Sanchez-del-Rio, Margarita https://orcid.org/0000-0001-7724-2890
García-Azorín, David
Peral, Carmen
Armada, Beatriz
Irimia-Sieira, Pablo
Porta-Etessam, Jesus https://orcid.org/0000-0002-7034-682X
- License Information
-
More Information
Article History
Received: 24 March 2025
Accepted: 9 May 2025
First Online: 15 May 2025
Declarations
:
: The NHWS received approval from the Pearl Institutional Review Board. All the NHWS respondents provided informed consent electronically prior to their participation.
: NA.
: Within the past 24 months, Dr. García-Azorín has received personal compensation for consulting/advising from the World Health Organization. Nonprofit board membership in the Spanish Society of Neurology, and the European Union of Medical Specialist section of Neurology. Research funding from the Regional Health Administration (Gerencia Regional de Salud SACYL) in Castilla y Leon, Carlos III Institute of Spain, and Eli Lilly. Speaker/travel grants/ clinical trials participation for Teva, Allergan/Abbvie, Amgen, Eli Lilly, Lundbeck, Novartis, and Biohaven. BA and CP are Pfizer employees. Within the past 24 months MSdR is the second vicepresident of the European Headache Federation. She has received personal fees as Speaker from Teva, Pfizer, Eli Lilly, Lundbeck and Organon.Within the past 24 months, Dr. Pablo Irimia has received personal fees for Speaker/travel grants from Teva, Allergan/Abbvie, Eli Lilly, Organon, Lundbeck, Novartis, and Pfizer.
